Innovus Pharma Signs Purchase Agreement with CVS Pharmacy, Inc. to Sell Its Product Androferti® to Increase Sperm Quality in Their Newly Established In-Store Men’s Clinic

CVS Men’s Health Clinic Pilot Program to Promote Androferti® in 12 to 20 Stores with the Potential, if Successful, to Expand Nationwide and Add Additional Products

SAN DIEGO--()--Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that it has entered into a pilot program with the nationwide pharmaceutical chain CVS Pharmacy, Inc. (“CVS”), which is a subsidiary of CVS Health Corp (NYSE: CVS), to sell the Company’s product Androferti®, to increase sperm quality. If successful, the CVS pilot program could lead to the national pharmacy stocking and selling Androferti® on a scalable level nationwide and could expand to add additional Innovus Pharma products.

“We are very pleased to have been chosen by CVS to be part of their newly established in-store men’s health clinic,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “In addition, we are in discussion to potentially add more product under this program.”

About Androferti

Androferti®, is a patented dietary supplement shown in multiple published clinical trials to statistically increase seminal quality (concentration, motility, morphology and vitality) and enhance spermatozoa quality (decreases of vacuoles in the sperm nucleus, decreases DNA fragmentation, decreases the dynamics of sperm DNA fragmentation, and improvement on the inventory of mobile sperm (“REM”)).

The Company believes that Androferti® is the only product clinically proven in multiple published clinical trials to increase the Sperm Quality and enhance Spermatozoa Quality as compared to other products where the claims are based primarily on an ingredient used in the products.

According to reports by IBIS World in August 2014, the fertility market is estimated to be around $2 billion with a 2.5% annual increase. There are currently 682 In-Vitro Fertility (IVF) clinics in the U.S. Androferti® is currently available directly to IVF clinics and online at www.myandroferti.com at a price of $95 per box, which is sufficient for a one month supply. For optimal results from the published clinical trials optimal results of Androferti® are observed with 3 months of continuous use.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and www.diabasens.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Androferti® product and other products, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.

Contacts

Randy Berholtz
Innovus Pharma Investor Relations
Tel: +1 858 249 7865
ir@innovuspharma.com

Contacts

Randy Berholtz
Innovus Pharma Investor Relations
Tel: +1 858 249 7865
ir@innovuspharma.com